My Stocks Explore Events Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Please signup to use this feature
Live today
{{event.ticker}} @{{event.event_utc_datetime | date:'h:mm a'}}
{{market.market_short_name}} {{market.last_price | number : 2}}
AlphaStreet

Want to join the conversation?


$GOOG {{ '2016-02-01T23:54:57+0000' | timeago}} • Webcast

Bernstein analyst Carlos Kirjner probes on site revenue growth drivers, and $GOOG $GOOGL CFO Ruth Porat says broad strength by product and geography, and the boost from the holidays helped site revenue.

User Jacob Bareto {{ '2016-12-05T21:04:55+0000' | timeago}}

Keep your eyes on $FLXN. This one could ascend rapidly. Great time to buy your favourite bio stocks. Make more $$$

User Amy Lewis {{ '2016-12-05T19:53:36+0000' | timeago}}

Bad for $AAPL. Despite a 3% increase in wearables shipments as per IDC, Apple Watch shipments plunged a whopping 71%. Smartwatches doesn't seem to take the lead nowadays, basic wearables like $FIT appear to be reigning supreme.

User Jacqueline Gallardo {{ '2016-12-05T19:06:29+0000' | timeago}}

$CRM on the pop today.. big bubble.

User Johney Kingston {{ '2016-12-05T17:47:57+0000' | timeago}}

Slumping and down the drain... $HDSN. Flush out your holdings !

User Dawn Martis {{ '2016-12-05T16:59:46+0000' | timeago}}

$KITE I am loving this one... really flying like a kite today :-)

$XRX {{ '2016-12-06T12:06:48+0000' | timeago}} • Announcement

$XRX appointed Joseph Echevarria, the former CEO of Deloitte LLP, and Cheryl Krongard, a former senior partner with Apollo Management LP, to its BoD effective Jan. 1, 2017. With these additions, $XRX Board will comprise 11 directors.

$CELG {{ '2016-12-06T12:03:36+0000' | timeago}} • Announcement

$CELG announced interim results from Abound clinical trial program evaluating use of Abraxane in patients with advanced non-small cell lung cancer (NSCLC). The study findings further support safety, efficacy and tolerability in squamous and elderly patients with advanced NSCLC, consistent with results previously seen in pivotal Phase 3 trial.

$PM {{ '2016-12-06T12:01:08+0000' | timeago}} • Announcement

$PM submitted on Dec. 5 a modified risk tobacco product (MRTP) application for its electronically heated tobacco product with the U.S. Food and Drug Administration's (FDA) Center for Tobacco Products. $PM expects FDA to take minimum of 60 days to complete administrative review to determine whether to accept application for substantive review.

$JNJ {{ '2016-12-06T11:56:46+0000' | timeago}} • Announcement

Janssen Research & Development, a $JNJ company, said new Ibrutinib (Imbruvica) phase 2 data demonstrate promise in relapsed/refractory marginal zone lymphoma (MZL), a rare incurable type of non-hodgkin's lymphoma. Janssen said half of patients with relapsed/refractory MZL responded to ibrutinib.

$CELG {{ '2016-12-06T11:48:40+0000' | timeago}} • Announcement

$CELG announced results from an analysis of three phase I/II studies evaluating CC-486 in patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML) who had received prior hypomethylating agents (HMA).